Harvest Capital Strategies LLC lifted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 14.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 63,000 shares of the company’s stock after acquiring an additional 8,000 shares during the period. Harvest Capital Strategies LLC’s holdings in Zoetis were worth $4,539,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. increased its position in Zoetis by 3.8% during the fourth quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock worth $2,772,498,000 after buying an additional 1,394,156 shares during the period. Clearbridge Investments LLC increased its position in Zoetis by 3.9% during the fourth quarter. Clearbridge Investments LLC now owns 9,512,060 shares of the company’s stock worth $685,249,000 after buying an additional 353,622 shares during the period. Brown Advisory Inc. increased its position in Zoetis by 2.1% during the fourth quarter. Brown Advisory Inc. now owns 7,207,114 shares of the company’s stock worth $519,200,000 after buying an additional 149,095 shares during the period. Janus Henderson Group PLC increased its position in Zoetis by 1.5% during the third quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock worth $375,792,000 after buying an additional 84,767 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in Zoetis by 1.3% during the fourth quarter. TIAA CREF Investment Management LLC now owns 5,648,528 shares of the company’s stock worth $406,920,000 after buying an additional 73,767 shares during the period. 92.45% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zoetis Inc (NYSE:ZTS) opened at $85.42 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. Zoetis Inc has a 12 month low of $52.25 and a 12 month high of $85.54. The firm has a market capitalization of $40,960.27, a P/E ratio of 48.34, a P/E/G ratio of 1.89 and a beta of 0.97.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.59%. Zoetis’s dividend payout ratio (DPR) is presently 28.57%.
ZTS has been the topic of several research analyst reports. Cowen set a $80.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. UBS Group reaffirmed a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 target price on Zoetis and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Craig Hallum reissued a “buy” rating and issued a $85.00 target price (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $80.28.
In other Zoetis news, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the sale, the executive vice president now directly owns 49,919 shares in the company, valued at $4,044,437.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,569 shares of company stock worth $8,594,429. Company insiders own 0.31% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.